These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25515347)

  • 1. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.
    Vashistha V; Quinn DI; Dorff TB; Daneshmand S
    BMC Cancer; 2014 Dec; 14():966. PubMed ID: 25515347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
    Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
    Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Meeks JJ; Bellmunt J; Bochner BH; Clarke NW; Daneshmand S; Galsky MD; Hahn NM; Lerner SP; Mason M; Powles T; Sternberg CN; Sonpavde G
    Eur Urol; 2012 Sep; 62(3):523-33. PubMed ID: 22677572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
    Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
    Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative therapy for muscle invasive bladder cancer.
    Leow JJ; Fay AP; Mullane SA; Bellmunt J
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):301-18, ix. PubMed ID: 25836936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
    Reardon ZD; Patel SG; Zaid HB; Stimson CJ; Resnick MJ; Keegan KA; Barocas DA; Chang SS; Cookson MS
    Eur Urol; 2015 Jan; 67(1):165-170. PubMed ID: 24472710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
    Makrakis D; Wright JL; Roudier MP; Garcia J; Vakar-Lopez F; Porter MP; Wang Y; Dash A; Lin D; Schade G; Winters B; Zhang X; Nelson P; Mostaghel E; Cheng HH; Schweizer M; Holt SK; Gore JL; Yu EY; Lam HM; Montgomery B
    Clin Genitourin Cancer; 2023 Apr; 21(2):265-272. PubMed ID: 36710146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
    Milowsky MI; Rumble RB; Booth CM; Gilligan T; Eapen LJ; Hauke RJ; Boumansour P; Lee CT
    J Clin Oncol; 2016 Jun; 34(16):1945-52. PubMed ID: 27001593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.
    Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
    Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
    Kim IH; Lee HJ
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.
    Leow JJ; Martin-Doyle W; Rajagopal PS; Patel CG; Anderson EM; Rothman AT; Cote RJ; Urun Y; Chang SL; Choueiri TK; Bellmunt J
    Eur Urol; 2014 Jul; 66(1):42-54. PubMed ID: 24018020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.
    Nadal R; Apolo AB
    Curr Treat Options Oncol; 2018 May; 19(7):36. PubMed ID: 29808294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.
    Gust KM; Rebhan K; Resch I; Shariat SF; Necchi A
    Curr Opin Urol; 2020 Jul; 30(4):547-556. PubMed ID: 32453001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.